[go: up one dir, main page]

UY37316A - SOLID PHARMACEUTICAL DISPERSION OF A BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITIONS OF THIS, AND USES FOR CANCER TREATMENT - Google Patents

SOLID PHARMACEUTICAL DISPERSION OF A BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITIONS OF THIS, AND USES FOR CANCER TREATMENT

Info

Publication number
UY37316A
UY37316A UY0001037316A UY37316A UY37316A UY 37316 A UY37316 A UY 37316A UY 0001037316 A UY0001037316 A UY 0001037316A UY 37316 A UY37316 A UY 37316A UY 37316 A UY37316 A UY 37316A
Authority
UY
Uruguay
Prior art keywords
bcl
inhibitor
cancer treatment
dispersion
pharmaceutical compositions
Prior art date
Application number
UY0001037316A
Other languages
Spanish (es)
Inventor
Caroline Chemin
Daya Verma
Emeric Reynaud
Ulrich Meier
Pean Jean-Manuel
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY37316A publication Critical patent/UY37316A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a formulaciones farmacéuticas en dispersión sólida de Compuesto A: y al uso de estas formulaciones para tratar cáncer.The invention relates to solid dispersion pharmaceutical formulations of Compound A: and the use of these formulations to treat cancer.

UY0001037316A 2016-07-07 2017-07-03 SOLID PHARMACEUTICAL DISPERSION OF A BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITIONS OF THIS, AND USES FOR CANCER TREATMENT UY37316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359366P 2016-07-07 2016-07-07
EP16182455 2016-08-02

Publications (1)

Publication Number Publication Date
UY37316A true UY37316A (en) 2018-01-31

Family

ID=56681951

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037316A UY37316A (en) 2016-07-07 2017-07-03 SOLID PHARMACEUTICAL DISPERSION OF A BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITIONS OF THIS, AND USES FOR CANCER TREATMENT

Country Status (3)

Country Link
TW (1) TW201805003A (en)
UY (1) UY37316A (en)
WO (1) WO2018007556A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376368B2 (en) 2018-11-06 2025-05-08 Beijing Innocare Pharma Tech Co., Ltd. Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (en) 2012-01-24 2014-02-21 Servier Lab NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3008979B1 (en) * 2013-07-23 2015-07-24 Servier Lab NOVEL PHOSPHATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
WO2018007556A1 (en) 2018-01-11
TW201805003A (en) 2018-02-16

Similar Documents

Publication Publication Date Title
MX2018016273A (en) HETEROCICLIC COMPOUNDS AS IMMUNOMODULATORS.
MX2023004593A (en) Tyk2 inhibitors and uses thereof.
ECSP19052302A (en) BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS
CL2018003135A1 (en) Aromatic derivatives of sulfonamide.
MX2018014154A (en) Modulatory polynucleotides.
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
CL2017002494A1 (en) Indolamine-2, 3- dioxygenase inhibitors for cancer treatment
MX383164B (en) COMPOSITION CONTAINING RNA FOR THE TREATMENT OF TUMOR DISEASES.
CL2016003422A1 (en) Lysine specific demethylase-1 inhibitors
DOP2015000274A (en) CHEMICAL COMPOUNDS
CL2016002735A1 (en) Imidazo [4,5-c] quinolin-2-one compounds and their use to treat cancer
MX2020011104A (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.
CL2016003423A1 (en) Lysine specific demethylase-1 inhibitors
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
SA519410320B1 (en) Phenyl-2-Hydroxy-Acetylamino-2-Methyl-Phenyl Compounds
DOP2018000238A (en) ZESTE HOMOLOGIST ENHANCER INHIBITORS 2
MX384798B (en) PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS.
MX379271B (en) Compounds for treatment of cancer
EA201790949A1 (en) SUBSTITUTED 2,4-DIAMINOCHINOLINES AS NEW ANTI-CANCER FACILITIES
MX2019001634A (en) AMIDAS COMPOUNDS, PHARMACEUTICAL COMPOSITIONS OF THESE AND METHODS TO USE THEM.
CR20160529A (en) PHARMACEUTICAL COMPOSITIONS TO TREAT INFECTIOUS DISEASES
BR112017002852A2 (en) azetidinyloxyphenylpyrrolidine compounds
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.
UY36217A (en) PIRIDONA SUBSTITUTE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
MX383386B (en) NEW BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS.